Table 5.
Multivariable Cox analysis for incident psoriasis according to eGFR.
| Proteinuria | Total (n) | Psoriasis (n) | IR (per 1000) | HR (95% CI) Model 3 | Proteinuria | Total (n) | Psoriasis (n) | IR (per 1000) | HR (95% CI) Model 3 |
|---|---|---|---|---|---|---|---|---|---|
| eGFR < 60 mL/min/1.73 m2 | eGFR ≥ 60 mL/min/1.73 m2 | ||||||||
| Never | 312,727 | 8848 | 3.96 | 1 (ref.) | Never | 6,010,748 | 146,565 | 3.37 | 1 (ref.) |
| Past | 12,695 | 427 | 4.88 | 1.13 (1.02–1.24) | Past | 107,033 | 2759 | 3.59 | 1.02 (0.98–1.06) |
| New | 13,018 | 474 | 5.40 | 1.24 (1.13–1.36) | New | 88,680 | 2270 | 3.59 | 1.01 (0.97–1.05) |
| Persistent | 10,075 | 454 | 6.86 | 1.52 (1.38–1.67) | Persistent | 21,875 | 671 | 4.35 | 1.16 (1.07–1.25) |
| p value | < 0.0001 | p value | 0.0023 | ||||||
| eGFR < 60 mL/min/1.73 m2 | eGFR ≥ 60 mL/min/1.73 m2 | ||||||||
| Negative | 314,640 | 8906 | 3.96 | 1 (ref.) | Negative | 5,999,048 | 146,402 | 3.37 | 1 (ref.) |
| trace | 10,782 | 369 | 4.90 | 1.16 (1.05–1.29) | Trace | 118,733 | 2922 | 3.42 | 0.99 (0.95–1.03) |
| 1+ | 11,831 | 432 | 5.37 | 1.22 (1.11–1.35) | 1+ | 76,414 | 1994 | 3.66 | 1.02 (0.98–1.07) |
| 2+ | 7750 | 318 | 6.21 | 1.40 (1.25–1.57) | 2+ | 26,590 | 750 | 3.98 | 1.09 (1.01–1.17) |
| 3+ | 2923 | 148 | 7.95 | 1.76 (1.50–2.08) | 3+ | 6430 | 159 | 3.52 | 0.94 (0.81–1.10) |
| 4+ | 589 | 30 | 8.11 | 1.79 (1.25–2.56) | 4+ | 1121 | 38 | 4.89 | 1.34 (0.98–1.84) |
| p trend | <0.0001 | p trend | 0.0817 | ||||||
Abbreviations: IR, incidence rate; HR, hazard ratio; Neg, no proteinuria; Pos, proteinuria present; eGFR, estimated glomerulus filtration rate; CI, confidence interval. Model 3: adjusted for age, sex, low income, smoking, alcohol drinking, physical activity, body mass index, hypertension, dyslipidemia, diabetes mellitus and estimated glomerular filtration rate.